Research Article - (2016) Volume 0, Issue 0

Effects of JNJ-54452840, an Anti-β1 Receptor Antibody Cyclopeptide in Heart Failure Patients: A Randomized, Double-blind, Parallel-group, Phase-2 Pilot Study

Stefan Störk1*, Alexei N Plotnikov2, Gary Peters2, Brian E Davies2, Ivo Nnane2, David Rivas2, Fisseha Tesfaye2, Stefan Kääb3,4, Axel Bauer3, Andreas Luchner5, Martin Ungerer6, Roland Jahns1,7, Martin Lohse1,8 and Georg Ertl1
1Comprehensive Heart Failure Center (CHFC), University of Würzburg, Germany
2Janssen Research and Development, LLC, New Jersey, USA
3Department of Medicine I–Cardiology, Ludwig-Maximillian’s University Hospital, Munich, Germany
4DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
5Department of Internal Medicine III - Cardiology, University of Tubingen, Germany
6AdvanceCor GmbH (formerly Procorde), Martinsried, Germany
7CHFC and Interdisciplinary Bank of Biomaterials and Data Würzburg, University Hospital of Würzburg, Germany
8Rudolf Virchow Center / DFG Research Center for Experimental Biomedicine, Würzburg, Germany
*Corresponding Author: